Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06447701 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis

Study acronym: IRIS-sICAS
StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 28, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Start date: Jun 30, 2024 to Oct 30, 2025v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Zhujiang Hospital
72 trials monitored
See 5 trials at risk
Stroke
3,289 trials monitored
See 141 trials at risk
IRIS-sICAS is a multicenter, randomized, double-blind, placebo-controlled clinical trialis a multicenter, randomized, double-blind, placebo-controlled clinical trial, to assess the safety and efficacy of tocilizumab injection in lowering the incidence of newly diagnosis ischemic stroke and improving prognosis in symptomatic intracranial atherosclerosis patients.
Trial Details
NCT Number NCT06447701
Lead Sponsor Zhujiang Hospital
Collaborators: Shenzhen Second People's Hospital, Central People's Hospital of Zhanjiang, Shantou Central Hospital, Eighth Affiliated Hospital, Sun Yat-sen University, Guangzhou First People's Hospital, Peking University Shenzhen Hospital, Guangdong Provincial People's Hospital
Conditions Brain Diseases, Ischemic Stroke, Ischemia, Stroke, Cerebral Infarction, Atherosclerosis of Artery, Atheroscleroses, Intracranial
Enrollment 486 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov